Proven
neurotechnology
built for the
real world
Control Bionics delivers objective, non-invasive neural-signal technology, proven in clinical environments, and built to scale across performance, rehabilitation, medical, research, and assistive communication.
Proven
neurotechnology
built for the
real world
Control Bionics delivers objective, non-invasive neural-signal technology, proven in clinical environments, and built to scale across performance, rehabilitation, medical, research, and assistive communication.
Capability
From signal to actionable insight
The Control Bionics neural-signal platform captures physiological data with medical-grade precision and converts it into measurable, decision-ready outcomes. Built for deployment across clinical, research, and performance environments — and validated where it counts.
Signal acquisition and processing
Real-time analysis and validation
Clinical integration and reporting
Technology
The platform serves distinct markets with precision and measurable outcomes. One underlying technology - four applications.
A platform built for clinical deployment
Medical-grade signal processing meets real-world clinical environments. Designed for integration, validation, and measurable outcomes.
Non-invasive neural signal capture
Physiological data without surgical intervention or implantation. Validated for use in complex clinical environments.
Regulatory pathway established
Cleared for clinical use with ongoing validation across multiple applications — FDA, TGA, and CE registered.
Outcome-focused architecture
Platform designed to deliver decision-ready insights, not only raw data. Built to integrate into clinical and research workflows.
Evidence from clinical and research deployment
Control Bionics technology is validated through research, clinical trials, and real-world deployment across rehabilitation, performance, and research settings.
1,000s of users
Trusted by individuals, clinicians, and organisations across four markets
Government and privately funded
Approved for funding through Medicare, Medicaid, NDIS, and private insurance pathways.
100%
Non-invasive signal acquisition
3 Regulatory clearances
(FDA, TGA, CE)
Latest from our platform
Research, clinical validation and platform developments.
Control Bionics’ (ASX:CBL) distinct tech feature – ‘Eye gaze combined with EMG switching’
Control Bionics was featured in an article by Kalkine Media discussing our NeuroNode Trilogy and its distinct tech feature. To deliver on our vision of giving a voice to those with physical and speech challenges, we have combined our NeuroNode Trilogy system with eye...
Navigating the Healthcare System in Canada: Three Webinars to Educate Yourself
It can be tricky to navigate the healthcare system in Canada, so we talked to experts in three new webinars.
Why Control Bionics’ (ASX:CBL) UNO Touch device points to a bright future
Control Bionics was featured in an article by Kalkine Media discussing our new AAC solution, UNO Touch.
Users with ALS Are Able to Utilize EMG Control with Facial Movement
Even ALS clients with minimal movement can utilize the NeuroNode Trilogy with the use of lead wire adapters.
Select your path to neural-signal insights and outcomes
Explore how the platform integrates into clinical workflows and delivers decision-ready outcomes.
Learn more
Discover how researchers are using real-time neural data to power breakthrough studies.
LearnNDIS-registered provider
Control Bionics is a registered NDIS provider. Eligible participants can access our assistive communication devices and neurotechnology solutions through their NDIS plan.